The moment of truth awaits Novo's diabetes pill: "It's really, really important"
Friday is the deadline for FDA's review of Novo Nordisk's diabetes tablet, oral semaglutide. Analysts anticipate an approval and blockbuster sales figures in future. Physician and patient association consider the drug "important for certain patients."
By Friday, the US Food and Drug Administration (FDA) will decide the fate of Novo Nordisk's diabetes tablet and future growth driver, oral semaglutide, and perhaps grant the drug its first and most important approval.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
